Collaborative Arrangements and Licensing Agreements (Tables)

12 Months Ended

Dec. 31, 2022

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2022, 2021 and 2020, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):

	Year Ended December 31,
	2022			2021			2020
SPINRAZA royalties (commercial revenue)	$	242.3		$	267.8		$	286.6
R&D revenue		124.4			161.0			122.0
Total revenue from our relationship with Biogen	$	366.7		$	428.8		$	408.6
Percentage of total revenue		62	%		53	%		56	%

AstraZeneca [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2022, 2021 and 2020, we earned the following revenue from our relationship with AstraZeneca (in millions, except percentage amounts):

	Year Ended December 31,
	2022			2021			2020
R&D revenue	$	79.2		$	254.6		$	88.0
Percentage of total revenue		13	%		31	%		12	%

GSK [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2022, 2021 and 2020, we earned the following revenue from our relationship with GSK (in millions, except percentage amounts):

	Year Ended December 31,
	2022		2021		2020
R&D revenue	$	—	$	—	$	0.2
Percentage of total revenue		—		—		—

Novartis [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2022, 2021 and 2020, we earned the following revenue from our relationship with Novartis (in millions, except percentage amounts):

	Year Ended December 31,
	2022		2021			2020
R&D revenue	$	0.2	$	25.5		$	1.0
Percentage of total revenue		—		3	%		—

Roche [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2022, 2021 and 2020, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):

	Year Ended December 31,
	2022			2021			2020
R&D revenue	$	67.2		$	17.2		$	5.9
Percentage of total revenue		11	%		2	%		1	%

Alnylam [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2022, 2021 and 2020, we earned the following revenue from our relationship with Alnylam (in millions, except percentage amounts):

	Year Ended December 31,
	2022			2021		2020
R&D revenue	$	21.4		$	—	$	47.9
Percentage of total revenue		4	%		—		7	%